300 related articles for article (PubMed ID: 27699258)
1. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
[TBL] [Abstract][Full Text] [Related]
2. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
[TBL] [Abstract][Full Text] [Related]
3. Panobinostat for the Treatment of Multiple Myeloma.
Laubach JP; Moreau P; San-Miguel JF; Richardson PG
Clin Cancer Res; 2015 Nov; 21(21):4767-73. PubMed ID: 26362997
[TBL] [Abstract][Full Text] [Related]
4. Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.
Imai Y; Maru Y; Tanaka J
Cancer Sci; 2016 Nov; 107(11):1543-1549. PubMed ID: 27554046
[TBL] [Abstract][Full Text] [Related]
5. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
[TBL] [Abstract][Full Text] [Related]
6. Deacetylase inhibitors: an advance in myeloma therapy?
Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
[TBL] [Abstract][Full Text] [Related]
7. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
Afifi S; Michael A; Azimi M; Rodriguez M; Lendvai N; Landgren O
Pharmacotherapy; 2015 Dec; 35(12):1173-88. PubMed ID: 26684557
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.
Baertsch MA; Hillengass J; Blocka J; Schönland S; Hegenbart U; Goldschmidt H; Raab MS
Hematol Oncol; 2018 Feb; 36(1):210-216. PubMed ID: 28685863
[TBL] [Abstract][Full Text] [Related]
9. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
10. Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.
Greig SL
Target Oncol; 2016 Feb; 11(1):107-14. PubMed ID: 26826025
[TBL] [Abstract][Full Text] [Related]
11. Panobinostat: first global approval.
Garnock-Jones KP
Drugs; 2015 Apr; 75(6):695-704. PubMed ID: 25837990
[TBL] [Abstract][Full Text] [Related]
12. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.
Ocio EM; Dávila J; Caballero JC; Alonso S; de la Calle VG; García-Sanz R; Gazi L; Opio S; Jiménez M; San-Miguel JF; Mateos MV
Haematologica; 2015 Jul; 100(7):e289-91. PubMed ID: 25795720
[No Abstract] [Full Text] [Related]
13. Panobinostat for the management of multiple myeloma.
Sivaraj D; Green MM; Gasparetto C
Future Oncol; 2017 Mar; 13(6):477-488. PubMed ID: 27776419
[TBL] [Abstract][Full Text] [Related]
14. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
Mu S; Kuroda Y; Shibayama H; Hino M; Tajima T; Corrado C; Lin R; Waldron E; Binlich F; Suzuki K
Eur J Clin Pharmacol; 2016 Feb; 72(2):153-61. PubMed ID: 26494130
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Ocio EM; Vilanova D; Atadja P; Maiso P; Crusoe E; Fernández-Lázaro D; Garayoa M; San-Segundo L; Hernández-Iglesias T; de Alava E; Shao W; Yao YM; Pandiella A; San-Miguel JF
Haematologica; 2010 May; 95(5):794-803. PubMed ID: 19951978
[TBL] [Abstract][Full Text] [Related]
16. Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
Wahaib K; Beggs AE; Campbell H; Kodali L; Ford PD
Am J Health Syst Pharm; 2016 Apr; 73(7):441-50. PubMed ID: 27001985
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Wolf JL; Siegel D; Goldschmidt H; Hazell K; Bourquelot PM; Bengoudifa BR; Matous J; Vij R; de Magalhaes-Silverman M; Abonour R; Anderson KC; Lonial S
Leuk Lymphoma; 2012 Sep; 53(9):1820-3. PubMed ID: 22288662
[No Abstract] [Full Text] [Related]
18. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Sato A; Asano T; Isono M; Ito K; Asano T
BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
[TBL] [Abstract][Full Text] [Related]
19. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
20. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Günther A; Lonial S; Einsele H
Expert Rev Hematol; 2017 Oct; 10(10):933-939. PubMed ID: 28885063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]